Visceral leishmaniasis: elimination with existing interventions

被引：86

作者：

Matlashewski, Greg ^{[2
,3
]}

Arana, Byron ^{[2
]}

Kroeger, Axel ^{[2
]}

Battacharya, Sujit ^{[2
,4
]}

Sundar, Shyam ^{[5
]}

Das, Pradeep ^{[6
]}

Sinha, Prabhat Kumar ^{[6
]}

Rijal, Suman ^{[7
]}

Mondal, Dinesh ^{[8
]}

Zilberstein, Dan ^{[3
,9
]}

Alvar, Jorge ^{[1
]}

机构：

[1] WHO, Dept Control Neglected Trop Dis, CH-1211 Geneva, Switzerland

[2] WHO, Special Programme Res & Training Trop Dis, CH-1211 Geneva, Switzerland

[3] McGill Univ, Dept Microbiol & Immunol, Montreal, PQ, Canada

[4] WHO, SE Asia Off, Delhi, India

[5] Banaras Hindu Univ, Inst Med Sci, Varanasi 221005, Uttar Pradesh, India

[6] Rajandra Mem Res Inst Med Sci, Patna, Bihar, India

[7] BP Koirala Inst Hlth Sci, Dharan, Nepal

[8] Int Ctr Diarrhoeal Dis Res, Dhaka 1000, Bangladesh

[9] Technion Israel Inst Technol, Fac Biol, Haifa, Israel

来源：

LANCET INFECTIOUS DISEASES | 2011年 / 11卷 / 04期

基金：

加拿大健康研究院;

关键词：

LIPOSOMAL AMPHOTERICIN-B; SINGLE; AMBISOME; INDIA;

D O I：

10.1016/S1473-3099(10)70320-0

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

The world's burden of infectious diseases can be substantially reduced by more-effective use of existing interventions. Advances in case detection, diagnosis, and treatment strategies have made it possible to consider the elimination of visceral leishmaniasis in the Indian subcontinent. The priority must now be to effectively implement existing interventions at the community level by actively finding cases in endemic villages and treating them with single-dose liposomal amphotericin B at primary-health-care centres. Once the elimination target of one case per 10 000 population has been reached, combination therapies involving miltefosine and paromomycin can be introduced to ensure long-term availability of several drugs for visceral leishmaniasis and to protect against resistance.

引用

页码：322 / 325

页数：4

共 27 条

[1] Control of phlebotomine sandflies [J].